are now a part of the new and improved


Dermwire News

News | April 8, 2019

Derm Students Improve Wikipedia Entries on Skin Disease, Boost Views

A group of medical students recruited to improve Wikipedia articles on skin-related diseases and saw millions more views of those stories following their editing, a new study shows. "We tried to make the articles more readable,...

Read More

News | March 28, 2019

PALLAS Ti: Sapphire Solid State Laser Shows Similar Efficacy and Safety to 308nm Excimer Laser for Localized Vitiligo

A novel 311nm Titanium:Sapphire UV laser demonstrates comparable efficacy and safety when compared to 308nm excimer laser in the treatment of localized vitiligo, according to a study recently published in Lasers in Surgery and...

Read More

News | April 16, 2019

Maine Gets SUNucated

Maine is joining 19 other states in allowing students to possess and use sunscreen in school. Governor Janet Mills signed LD 441, which was sponsored by Senator Cathy Breen. Modeled after American Society for Dermatologic Surgery...

Read More

News | April 2, 2019

Encore Dermatology Acquires Marketing Rights to Promius Pharma Brands

Encore Dermatology is purchasing the US rights to market Sernivo® (betamethasone dipropionate) Spray, 0.05% and is being assigned the rights to market and distribute Promiseb® Topical Cream and Trianex® 0.05%...

Read More
Thumbnail for gvhiwine
Play Button

Updates from Principia, Sebacia, and Candela

Series: DermWire TV | March 21, 2019

Phase 2 data for from the Believe-PV study for PRN1008 show that the investigational agent from Principia Biopharma reached the primary efficacy measure in pemphigus. Data confirm that Sebacia microparticles confer benefit in the management of acne vulgaris in real-world settings. Candela has rebranded to reflect the unification of the Syneron and Candela brands. Dupixent from Regeneron Pharmaceuticals and Sanofi is now approved to treat atopic dermatitis in patients ages 12 through 17.

Watch Video


The Latest News


View more